0 rating


Wilson AM, Shin DS, Weatherby C et al.

Stanford University Medical Center, Stanford, CA, USA.

 Vasc Med 2010;15:267–74.

Editor’s note: Interest in biomarkers (generally molecular constituents of the blood) has intensified over the past decade. It is appropriate to consider biomarkers in two broad categories: markers of disease without necessarily direct involvement in the pathogenesis of the disease and markers of a pathophysiological process that underlies or contributes to exacerbation of disease. Asymmetric dimethylarginine (ADMA) appears to be a marker that falls in the latter category.

Return to top